Rosemarie de Haan

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells

Caroline V.M. Verhagen, Rosemarie de Haan, Floor Hageman et al. · Radiotherapy and Oncology · 2015 · 111 citations

Parp Inhibitor Olaparib, Radiation Therapy, Radiobiology +10

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

Rosemarie de Haan, Michel M. van den Heuvel, Judi van Diessen et al. · Clinical Cancer Research · 2020 · 54 citations · Full text

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

Rosemarie de Haan, Erik van Werkhoven, Michel M. van den Heuvel et al. · BMC Cancer · 2019 · 47 citations · Full text

Retinal Arteriolar Geometry is Associated with Cerebral White Matter Hyperintensities on Magnetic Resonance Imaging

Fergus Doubal, Rosemarie de Haan, Petra E. Cohn‐Hokke et al. · International Journal of Stroke · 2010 · 42 citations · Full text

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials

Rosemarie de Haan, Dick Pluim, Baukelien van Triest et al. · Radiotherapy and Oncology · 2017 · 23 citations · Full text